Sigyn Therapeutics will begin trading on the OTCQB® Venture Exchange

SAN DIEGO, California, August 03, 2022 (GLOBE NEWSWIRE) – via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage medical technology company focused on unmet needs in global health, announces that its securities will begin trading on the OTCQB® Venture Exchange when the market opens in today. The Company’s securities, which previously traded on the over-the-counter pink market, will continue to trade under the symbol “SIGY”.

To address unmet global health needs, the company is advancing Sigyn Therapy™, a broad-spectrum blood purification technology that extracts infectious viruses, bacterial toxins and potentially deadly inflammatory mediators from the bloodstream. Possible treatment options include sepsis (leading cause of hospital death), community acquired pneumonia (a leading cause of infectious disease death), emerging pandemic threats, and inflammation and endotoxemia of end-stage renal failure (ESRD).

“Along with our advancement of Sigyn Therapy, graduating our credentials to the OTCQB is a natural evolution in our quest to list on a major exchange,” said Jim Joyceco-founder and CEO of Therapeutic Sigyn. “We thank the OTC Markets Group team for approving our application.”

Previously, Mr Joyce (Founder, former Chairman and CEO of Aethlon Medical) oversaw the development of the Aethlon Hemopurifier®, a broad-spectrum blood purification technology to combat life-threatening viruses. During Mr. Joyce’s tenure, the haemopurifier became the first therapeutic candidate to receive two “Breakthrough Device” designations from the United States Food and Drug Administration (FDA) and was named “Top 25 Inventions” and one of the “11 Most Remarkable Advancements in Healthcare” by Time magazine.

About OTCQB® Venture capital market

The OTCQB® Venture Market, operated by OTC Markets Group, is for the entrepreneurial and development phase WE and international companies. To be eligible for OTCQB ratings, companies must be up-to-date with their disclosure statements, have audited financial statements, and undergo an annual management validation and certification process. Businesses must also meet minimum bid tests and other financial conditions. The OTCQB is recognized as a public market established by the Security and Exchange Commission and provides up-to-date public information to investors in need of securities analysis, valuation and trading.

About Sigyn Therapeutics™

Therapeutic Sigyn is a development-stage company focused on addressing unmet needs in global health. Sigyn Therapy™ is a broad-spectrum blood purification technology that extracts infectious viruses, bacterial toxins and life-threatening inflammatory mediators from the bloodstream. Based on these capabilities, candidate treatment indications for Sigyn Therapy include disorders associated with pathogens that precipitate sepsis (a leading cause of death in hospital), community-acquired pneumonia (a leading cause of death among infectious diseases), emerging pandemic threats, inflammation and endotoxemia in dialysis patients with end-stage renal disease (ESRD). According to WE Renal Data System, approximately 550,000 people suffer from ESRD in United States.

To learn more, visit www.SigynTherapeutics.com

Caution Regarding Forward-Looking Statements

The information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) which involve substantial risks and uncertainties. All statements in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may”, “believe”, “anticipate”, “expect”, “intend”, “plan”, “project”, “will”, “projections”, ” estimate”, “potentially” or similar expressions constitute forward-looking statements. These forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based on Sigyn’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to these differences may include, but are not limited to, the Company’s ability to clinically advance Sigyn Therapy in the human studies required for marketing authorization, the Company’s ability to manufacture Sigyn Therapy, the Company’s ability to raise capital resources and other potential risks. The above list of risks and uncertainties is illustrative but not exhaustive. Other factors that could cause actual results to differ materially from those anticipated in the forward-looking statements can be found under “Risk Factors” in the company’s Annual Report on Form 10-K for the fiscal year ended. December 31, 2021and in other documents filed by the Company with the Security and Exchange Commissionincluding its quarterly reports on Form 10-Q. All the forward-looking statements contained in this report speak only as of the date on which they were made. Except as required by law, the Company does not intend, nor undertakes any obligation, to update this information to reflect future events or circumstances.

contacts:

Stephen KilmerSigyn Therapeutics, Inc.
Investor Relations
(646) 274-3580
[email protected]

main logo

Source: Sigyn Therapeutics, Inc.

2022 GlobeNewswire, Inc., source Press Releases

Comments are closed.